ArticleExperimental hematology & oncology2026
Functional xenogeneic hematopoietic cells maintaining donor-dominant identity and immune tolerance enable therapy.
Article in Experimental hematology & oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The making of cells and organs in xenogeneic animal bioreactor.Signal transduction and targeted therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThe clinical supply of hematopoietic cells is severely constrained by the limitations of donor donation and inefficient in vitro generation. While generating these cells within interspecies chimeras presents a groundbreaking alternative, the fundamental biological properties and therapeutic potential of the resulting xenogeneic hematopoietic cells remain poorly characterized.
methodsWe generated xenogeneic hematopoietic cells in rodent models via blastocyst complementation and bone marrow transplantation. A comprehensive comparative analysis of these cells was conducted using single-cell RNA sequencing and proteomics. Their functional efficacy was rigorously evaluated through reverse transplantation into a series of donor-species disease models, including hemorrhagic anemia, thalassemia, thrombocytopenia, and leukemia.
resultsBone marrow transplantation yielded significantly higher chimeric efficiency than blastocyst complementation. Xenogeneic hematopoietic cells, including red blood cells, platelets, and white blood cells, exhibited a transcriptional and proteomic profile that was dominantly donor-specific. Crucially, these cells did not elicit significant immune rejection upon reverse transfusion. Functionally, xenogeneic red blood cells rescued models of hemorrhagic anemia and thalassemia, platelets alleviated thrombocytopenia, and xenogeneic T cells engineered with a chimeric antigen receptor effectively suppressed leukemia progression. Furthermore, the implantation of xenogeneic hematopoietic cells partially reconstituted splenic morphology and function in immunodeficient recipients.
conclusionOur study provides the first comprehensive functional validation of xenogeneic hematopoietic cells generated in interspecies bioreactors. We definitively show that these cells possess donor-like molecular identities, evade immune rejection, and serve as effective "seed cells" to rescue a wide spectrum of hematologic diseases. This work establishes a transformative paradigm for utilizing interspecies chimeras to overcome critical shortages in transfusion and cellular therapies.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.